Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic, immune-mediated inflammatory disorder of the gastrointestinal tract. Immunosuppressive therapy administration increases the risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactiv...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/15/6/893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850167808767295488 |
|---|---|
| author | Yueh-An Lee Hsu-Heng Yen Yang-Yuan Chen |
| author_facet | Yueh-An Lee Hsu-Heng Yen Yang-Yuan Chen |
| author_sort | Yueh-An Lee |
| collection | DOAJ |
| description | Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic, immune-mediated inflammatory disorder of the gastrointestinal tract. Immunosuppressive therapy administration increases the risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation. This study aimed to investigate the hepatitis screening rate, serological status, and protective antibody levels among the Taiwanese IBD population. This single-center retrospective study included patients with IBD from January 2016 to December 2024. Hepatitis serological markers were analyzed. Patients were categorized into active HBV infection (HBsAg-positive), resolved HBV infection (HBsAg-negative and anti-HBc-positive), and non-HBV-infected groups, with prevalences of 7.5%, 32.5%, and 0.9%, respectively. This study included 347 patients with IBD (UC: 68.3%; CD: 31.7%), with a mean age of 47.1 ± 16.4 years. Patients born after 1984 demonstrated a significantly reduced HBsAg positivity (0.9% vs. 11.0%; <i>p</i> < 0.05) and resolved HBV infection (52.2% vs. 1.0%; <i>p</i> < 0.05). However, among non-HBV-infected individuals, only 42.0% had protective anti-HBs levels (≥10 mIU/mL), despite vaccination program initiation. In this study, we found an overall HBsAg positivity rate of 7.5% and an anti-HCV seropositivity rate of 0.9% in our IBD population. Taiwan’s HBV vaccination program has effectively reduced the HBV prevalence. However, a significant proportion of vaccinated individuals lack sufficient protective antibody levels, thereby requiring continued HBV screening and booster vaccinations. |
| format | Article |
| id | doaj-art-db9dbdfaabe14688bc81d630036a0a85 |
| institution | OA Journals |
| issn | 2075-1729 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-db9dbdfaabe14688bc81d630036a0a852025-08-20T02:21:07ZengMDPI AGLife2075-17292025-05-0115689310.3390/life15060893Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort AnalysisYueh-An Lee0Hsu-Heng Yen1Yang-Yuan Chen2Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, TaiwanInflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic, immune-mediated inflammatory disorder of the gastrointestinal tract. Immunosuppressive therapy administration increases the risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation. This study aimed to investigate the hepatitis screening rate, serological status, and protective antibody levels among the Taiwanese IBD population. This single-center retrospective study included patients with IBD from January 2016 to December 2024. Hepatitis serological markers were analyzed. Patients were categorized into active HBV infection (HBsAg-positive), resolved HBV infection (HBsAg-negative and anti-HBc-positive), and non-HBV-infected groups, with prevalences of 7.5%, 32.5%, and 0.9%, respectively. This study included 347 patients with IBD (UC: 68.3%; CD: 31.7%), with a mean age of 47.1 ± 16.4 years. Patients born after 1984 demonstrated a significantly reduced HBsAg positivity (0.9% vs. 11.0%; <i>p</i> < 0.05) and resolved HBV infection (52.2% vs. 1.0%; <i>p</i> < 0.05). However, among non-HBV-infected individuals, only 42.0% had protective anti-HBs levels (≥10 mIU/mL), despite vaccination program initiation. In this study, we found an overall HBsAg positivity rate of 7.5% and an anti-HCV seropositivity rate of 0.9% in our IBD population. Taiwan’s HBV vaccination program has effectively reduced the HBV prevalence. However, a significant proportion of vaccinated individuals lack sufficient protective antibody levels, thereby requiring continued HBV screening and booster vaccinations.https://www.mdpi.com/2075-1729/15/6/893hepatitisinflammatory bowel diseasevaccination |
| spellingShingle | Yueh-An Lee Hsu-Heng Yen Yang-Yuan Chen Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis Life hepatitis inflammatory bowel disease vaccination |
| title | Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis |
| title_full | Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis |
| title_fullStr | Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis |
| title_full_unstemmed | Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis |
| title_short | Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis |
| title_sort | serological assessment of hepatitis in patients with inflammatory bowel disease in taiwan a retrospective cohort analysis |
| topic | hepatitis inflammatory bowel disease vaccination |
| url | https://www.mdpi.com/2075-1729/15/6/893 |
| work_keys_str_mv | AT yuehanlee serologicalassessmentofhepatitisinpatientswithinflammatoryboweldiseaseintaiwanaretrospectivecohortanalysis AT hsuhengyen serologicalassessmentofhepatitisinpatientswithinflammatoryboweldiseaseintaiwanaretrospectivecohortanalysis AT yangyuanchen serologicalassessmentofhepatitisinpatientswithinflammatoryboweldiseaseintaiwanaretrospectivecohortanalysis |